login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

First patients treated with Chemosat in Germany


Tuesday, 28 Feb 2012 11:12
Chemosaturation
Chemosaturation

Delcath Systems announced on 27 February that the first patients in Germany have been treated with the Delcath Hepatic Chemosat Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the company announced with the hospital in December 2011.


Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.


Thomas J Vogl, director of the Institute for Diagnostic and Interventional Radiology at JW Goethe, said, “We believe this technology has significant potential to help control cancers in the liver. We are pleased to be the first cancer centre to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer.”


“Delcath’s partnership with JW Goethe reinforces the potential of Chemosat,” said Eamonn P Hobbs, president and CEO, Delcath. “We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another Chemosat treatment centre and treating patients in the continent’s largest market is another step forward in the commercialisation of this technology.”




Add New Comment

Related Items


Most popular


New varicose vein treatment available in Europe
Monday, 16 Feb 2015
VariClose is a new technique by which an incompetent saphenous vein is sealed through embolisation. New varicose vein treatment available in Europe

IN.PACT Admiral drug-eluting balloon receives FDA approval
Monday, 05 Jan 2015
In the IN.PACT SFA trial, the device demonstrated the lowest clinically-driven target lesion revascularisation rate (2.4%) ever reported for an interventional treatment of peripheral arterial disease ... IN.PACT Admiral drug-eluting balloon receives FDA approval

Medtronic completes acquisition of Covidien
Tuesday, 27 Jan 2015
Under the terms of the acquisition agreement, Medtronic Inc and Covidien plc are now combined under Medtronic plc. Medtronic completes acquisition of Covidien

Features


“We are helping surgeons operate on sicker patients”
Wednesday, 25 Feb 2015
Daniel B Brown, Vanderbilt-Ingram Cancer Center, Nashville, USA, puts together a 2015 checklist on the latest portal vein embolization developments for Interventional News readers. “We are helping surgeons operate on sicker patients”

SIR 2015: Take home new skills and perspectives from Atlanta
Thursday, 15 Jan 2015
Jafar Golzarian, SIR 2015’s programme chair, discusses some of the most exciting sessions from the Society of Interventional Radiology’s (SIR’s) upcoming Annual Scientific Meeting (28 February–5 M... SIR 2015: Take home new skills and perspectives from Atlanta

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions